Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC1416
- Development stage
- Phase 2
- Lead developer
- Nanjing RegeneCore Biotech
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
RC1416 is a recombinant bispecific nanobody (single domain antibody) injection developed by Nanjing RegeneCore Biotech. It targets both interleukin 4 receptor subunit alpha (IL-4Rα) and interleukin 5 (IL-5), functioning as an inhibitor of these pathways. The drug is designed to block the signaling of IL-4, IL-5, and potentially IL-13 pathways—key mediators in Th2-type immune responses—thereby reducing inflammation associated with diseases like moderate to severe asthma. Its primary clinical indication is as an add-on maintenance therapy for patients with moderate to severe asthma who are already on standard treatments. The drug has reached Phase 1 clinical trials in China and the United States[1][2][3][7].
- Other names
- Anti-IL-4R/IL-5 bispecific antibodyRecombinant anti-human IL-4Rα and IL-5 single domain antibody
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)IL-5 (Interleukin 5)
Beyond the preview
Go deeper on RC1416.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC1416.